Get started
Author

Erica Palesandro

Observed names: E. Palesandro, ERICA PALESANDRO, Palesandro, Erica
Observed institutions: Ospedale Civile Edoardo Agnelli, Azienda Ospedaliero Universitaria San Giovanni Battista, Ospedale Civile Di Ivrea, Azienda Sanitaria Locale di Asti, Candiolo Cancer Institute, Ospedale San Luigi Gonzaga, University of Turin
ORCID: 0000-0002-3960-7964
Observed ORCID: 0000-0002-3960-7964
OpenAlex ID: A5025970177
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
2017 · Ymera Pignochino, Federica Capozzi, et al. · Molecular Cancer · 72
PDF
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024 · Brigida Anna Maiorano, Massimo Di Maio, et al. · JAMA Network Open · 61
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?
2011 · Fabrizio Carnevale-Schianca, Susanna Gallo, et al. · Journal of Clinical Oncology · 42
PDF
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour
2017 · Lorenzo D'Ambrosio, Erica Palesandro, et al. · European Journal of Cancer · 38
Alpha–fetoprotein elevation in NUT midline carcinoma: a case report
2017 · Lorenzo D’Ambrosio, Erica Palesandro, et al. · BMC Cancer · 20
PDF
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
2019 · Gaetano Facchini, Sabrina Rossetti, et al. · Journal of Translational Medicine · 19
PDF
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
2021 · Orazio Caffo, Cinzia Ortega, et al. · European Journal of Cancer · 18
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials
2024 · Marcello Tucci, Marta Mandarà, et al. · Cancer Treatment Reviews · 10
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave
2020 · Valentina Bertaglia, Maria Lucia Reale, et al. · Critical Reviews in Oncology/Hematology · 7
PDF
A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
2019 · Orazio Caffo, Erica Palesandro, et al. · Journal of Clinical Oncology · 7
Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature
2012 · Danilo Galizia, Erica Palesandro, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 7
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
2024 · Fabio Turco, Consuelo Buttigliero, et al. · Clinical Genitourinary Cancer · 6
PDF
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit
2020 · Maria Lucia Reale, Paolo Bironzo, et al. · Frontiers in Oncology · 5
PDF
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
2018 · ANDREA SBRANA, ELISA BIASCO, et al. · Anticancer Research · 5
PDF
A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.
2016 · Giovanni Grignani, Lorenzo D'Ambrosio, et al. · Journal of Clinical Oncology · 5
Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist
2025 · Angelo Del Gaudio, Loris Riccardo Lopetuso, et al. · Therapeutic Advances in Gastroenterology · 3
Is [177Lu]Lu-PSMA-617 Redefining Value in mCRPC Care? A Meta-Analysis of Clinical and Economic Endpoints
2025 · Francesco Fiorica, Maria Viviana Candela, et al. · Cancers · 3
PDF
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published Data
2025 · Francesco Fiorica, Teodoro Sava, et al. · Cancers · 3
PDF
Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.
2018 · Zuzana Sirotova, Giulia Courthod, et al. · Journal of Clinical Oncology · 2
Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST).
2011 · L. D'Ambrosio, A. Ponzetti, et al. · Journal of Clinical Oncology · 2
Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations
2025 · Carla Colombo, Simone De Leo, et al. · Critical Reviews in Oncology/Hematology · 1
PDF
A risk-based individualized follow-up after complete surgery as an effective procedure to reduce the relapse (R) impact in GIST patients (pts).
2013 · Erica Palesandro, Danilo Galizia, et al. · Journal of Clinical Oncology · 1
Abstract LB-213: The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS).
2013 · Ymera Pignochino, Federica Capozzi, et al. · Cancer Research · 1
Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC).
2011 · D. Galizia, C. Ortega, et al. · Journal of Clinical Oncology · 1
Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel
2026 · Francesco Mattana, Erica Palesandro, et al. · Cancer Treatment Reviews
Works count: 42
Citation count: 339
H-index: 8
I10-index: 8
Year
Topic
Type